Milvexian did not reduce ischemic risk in recent ACS

MUNICH — Milvexian did not lower risk for ischemic events compared with placebo in patients who experienced a recent ACS, but also did not increase bleeding risk, a speaker reported.
The LIBREXIA trial evaluating the small-molecule factor XIa inhibitor milvexian (Bristol Myers Squibb/Johnson & Johnson) in patients at risk for recurrent ischemic events after an ACS event was halted early for futility, according to results presented at the European Society of Cardiology Congress and simultaneously published in The New England Journal of Medicine.
“Milvexin is an oral factor XIa

Repatha before PCI for acute MI improves lipids but not outcomes

MUNICH — Early administration of evolocumab prior to PCI for acute MI significantly improved patients’ chances of meeting guideline-recommended LDL goals by 1 year, but did not impact clinical outcomes vs. standard care.
Fewer patients who received standard care alone achieved LDL control at 1 year compared with those who initiated evolocumab (Repatha, Amgen) prior to PCI on top of standard care, according to the results of the AMUNDSEN trial presented at the European Society of Cardiology Congress and simultaneously published in JAMA.
“In the AMUNDSEN trial, we had two

Statins cut risk for first heart attack, stroke by 30% after age 70

MUNICH — Statin therapy cut risk for major adverse CV events by 30% for healthy older adults compared with placebo, but did not extend disability-free survival, according to data presented at the European Society of Cardiology Congress.
The benefits and risks of initiating statin therapy are not as clear among older adults without previous CV events and evidence is particularly sparse for people aged 75 years and older, Sophia Zoungas, MBBS(Hons), PhD, FRACP, FAHMS, executive director of The George Institute for Global Health Australia, said during a Hot Line presentation of the STAREE

New global definition of MI simplifies diagnosis, patient care

MUNICH — Myocardial infarctions will now fall under one of three clinical categories as part of a simplified universal definition, a multi-society effort to eliminate diagnostic uncertainty for patients, clinicians and researchers.
The Fifth Universal Definition of MI, which was unveiled at the European Society of Cardiology Congress, is an update to the previous five numerical labels designed to align more with the underlying pathophysiology.
“It was about time that the ‘universal’ definition of MI became universal,” George D. Dangas, MD, PhD, MACC, MSCAI, an author/task force member for the